A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Fezolinetant (also called Veoza and made by Astellas ...
What you need to know The prevalence of heart failure across Europe is estimated to be 1-2% of adults.1 In the UK, this places a substantial burden on patients and healthcare resources, including ...
Hosted on MSN
Prostate cancer patients could avoid overtreatment if NICE updated its guidelines, charity says
Up to 5,000 men a year could avoid potentially harmful treatment for prostate cancer if ‘outdated’ guidelines reflected the latest evidence, a charity has said. Closely monitoring the disease with ...
GPs are to be given a new non-hormonal prescribing option for menopausal hot flushes and night sweats, as NICE has expressed its support for fezolinetant. Final NICE draft guidance issued today ...
The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...
The National Institute for Health and Care Excellence (NICE) has recommended abaloparatide (Eladynos, Theramex) as an option for treating osteoporosis after menopause in women, trans men, and ...
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results